The U.S. FDA has approved Merck’s Keytruda Qlex, the first subcutaneous immune checkpoint inhibitor administered in about one minute. This new administration method offers a significant reduction from the traditional 30-minute intravenous infusion. Keytruda remains a blockbuster anti-PD-1 therapy for solid tumors, and this advancement is expected to improve patient convenience and healthcare facility efficiency. The approval underscores innovation in cancer immunotherapy delivery modalities.